MHE Talks: Patient Access to Multiple Sclerosis Care with Thomas P. Leist of Jefferson University Hospitals

Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS

Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.

Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.

Women are at risk for disease progression when they stop treatment for multiple sclerosis during pregnancy.

As with adult-onset MS, early treatment of pediatric-onset MS (POMS) is essential to halt disease progression, including early disability, brain volume loss, and cognitive impairment.